Lexaria Bioscience(LEXX)

Search documents
Lexaria Bioscience Corp. Provides Strategic Update
Thenewswire· 2025-10-09 13:20
Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities Lexaria Awarded 4 New Patents Kelowna, British Columbia - October 9, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide the following strategic business update. For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across a number of s ...
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thenewswire· 2025-09-29 20:30
Kelowna, British Columbia - September 29, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share. In addition, in a concurrent private placement, the Company issued unregist ...
Lexaria Bioscience announces ~$4M registered direct offering of shares (LEXX:NASDAQ)
Seeking Alpha· 2025-09-26 12:18
Lexaria Bioscience (NASDAQ:LEXX) was trading lower after the drug delivery platform announced a sale of 2,666,667 shares, par value $0.001 per share, at $1.50 per share in a registered direct offering. Gross proceeds are expected to be ~$4.0M. Shares were ...
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thenewswire· 2025-09-26 12:10
Kelowna, British Columbia – TheNewswire - September 26, 2025 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private ...
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket - Apellis Pharmaceuticals (NASDAQ:APLS)
Benzinga· 2025-09-26 10:25
Key Points - Top KingWin Ltd (NASDAQ: WAI) shares increased by 87.4% to $5.92 in pre-market trading after announcing a sales contract with Walker Times International for 10,000 units of TK-D2C AI Robots [1] - MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) saw a significant rise of 242% to $4.96 in pre-market trading due to plans to double the installation of its Authentication Device "Orb" to 200 stores in collaboration with "World" [5] - New Era Energy & Digital, Inc. (NYSE: NUAI) surged 37.6% to $1.90 in pre-market trading after a previous 50% increase [5] - Datavault AI Inc. (NASDAQ: DVLT) gained 33% to $1.11 in pre-market trading after securing a $150 million investment in Bitcoin to build a supercomputer [5] - Harrison Global Holdings Inc. (NASDAQ: BLMZ) increased by 28.3% to $0.2288 in pre-market trading [5] - Lexaria Bioscience Corp. (NASDAQ: LEXX) rose 28.1% to $1.96 in pre-market trading after ending its "Capital on Demand" Sales Agreement with JonesTrading Institutional Services LLC [5] - Safety Shot, Inc. (NASDAQ: SHOT) gained 14.8% to $0.2868 in pre-market trading following a partnership with Monarq Asset Management [5] - Diginex Limited (NASDAQ: DGNX) jumped 13.6% to $15.00 in pre-market trading after a previous decline of 16% [5] - GLOBALFOUNDRIES Inc. (NASDAQ: GFS) increased by 9.9% to $36.09 in pre-market trading [5] - American Rebel Holdings, Inc. (NASDAQ: AREB) surged 9.7% to $1.13 after announcing a 1-for-20 reverse stock split [5] - Kuke Music Holding Limited (NYSE: KUKE) dipped 30.5% to $0.8200 after acquiring a controlling interest in Naxos Music Group [5] - Wellgistics Health, Inc. (NASDAQ: WGRX) fell 24.3% to $0.7598 after announcing a $5 million public offering [5] - Wolfspeed, Inc. (NYSE: WOLF) shares decreased by 24% to $1.41 after a decline of around 17% on Thursday [5] - Concentrix Corporation (NASDAQ: CNXC) declined 20.5% to $43.73 after reporting worse-than-expected third-quarter adjusted EPS results and cutting FY25 adjusted EPS guidance [5] - DarioHealth Corp. (NASDAQ: DRIO) fell 18.9% to $11.10 after a previous jump of 44% following a strategic review [5] - N2OFF, Inc. (NASDAQ: NITO) declined 13.7% to $4.75 after stockholders approved the acquisition of MitoCareX Bio [5] - Legacy Education Inc. (NYSE: LGCY) fell 13.3% to $10.68 after reporting worse-than-expected fourth-quarter EPS results [5] - Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) dipped 9.5% to $20.12 in pre-market trading [5] - Pharming Group N.V. (NASDAQ: PHAR) fell 9.1% to $13.45 in pre-market trading [5] - Kingsoft Cloud Holdings Limited (NASDAQ: KC) decreased by 7.5% to $16.15 after announcing the pricing of an upsized HK$2,802 million offering of new shares [5]
Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID
RTTNews· 2025-09-26 03:55
Core Insights - Several small-cap stocks experienced significant gains in after-hours trading due to corporate updates, clinical developments, and strategic shifts Company Summaries MEDIROM Healthcare Technologies Inc. (MRM) - Shares surged 282.8% to $5.55 after announcing plans to double the installation of its biometric authentication device "Orb" to 200 stores in collaboration with "World" [2] - Closed at $1.45 during regular trading, down 7.05%, with a trading volume of over 31.5 million shares [3] - The stock has a 52-week range of $0.34 to $5.30, highlighting the scale of its overnight move [3] Lexaria Bioscience Corp. (LEXX) - Shares rose 45.75% to $2.23 following renewed interest in its DehydraTECH drug delivery platform, which enhances GLP-1 drug delivery [4] - Closed at $1.53, up 7.75%, with a volume exceeding 7.5 million shares [5] - The stock's 52-week range is $0.775 to $3.392, with Thursday's close near the midpoint [5] Safety Shot, Inc. (SHOT) - Shares increased 12% to $0.28 after announcing a partnership with Monarq Asset Management to manage its BONK Holdings Treasury [6] - Closed at $0.25, down 9.06%, with a trading volume of over 15.4 million shares [7] - The stock has a 52-week range of $0.23 to $1.35, with the after-hours price near the lower end [7] Aquestive Therapeutics, Inc. (AQST) - Shares rose 11.41% to $5.86 following favorable regulatory news regarding its oral epinephrine candidate, Anaphylm [8] - Closed at $5.26, down 2.95%, with a volume of over 3.6 million shares [9] - The stock's 52-week range is $2.12 to $6.00, with the after-hours price near the upper end [9] Ovid Therapeutics Inc. (OVID) - Shares increased 4.26% to $1.47 after reaching a 52-week high during regular trading, driven by progress in its neurological pipeline [10] - Closed at $1.41, up 0.71%, with a trading volume of over 2.4 million shares [11] - The stock has a 52-week range of $0.2430 to $1.47, with Thursday's close at the top end of its recent performance band [11]
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Thenewswire· 2025-09-19 15:20
Core Insights - The study conducted by Lexaria Bioscience Corp. indicates that the DehydraTECH processing of semaglutide enhances its brain biodistribution compared to conventional formulations, potentially improving safety and efficacy [1][3][6] Study Findings - The primary objective of the study was to assess whether DehydraTECH processing significantly improves the biodistribution of semaglutide [2] - The DehydraTECH-FTS composition showed a higher apparent trend in brain biodistribution across all tested doses, with the 5mg DehydraTECH-FTS achieving greater brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent [3][5] - Fluorescent imaging revealed that all three DehydraTECH doses tested had higher fluorescence in key brain regions compared to naïve and vehicle groups, while only the highest dosage of Rybelsus® surpassed these groups [5] Mechanism and Implications - The study suggests that enhanced brain biodistribution may be linked to the pharmacodynamic performance of GLP-1 drugs, which are known to interact with brain neurochemistry [6][7] - Semaglutide's ability to regulate body weight through GLP-1 receptor activation in the brain could lead to appetite suppression without common side effects like nausea [6] - Lexaria's findings may support the development of safer and more effective GLP-1 drugs in the future [8] Research Methodology - The preclinical pilot study involved Sprague Dawley rats and utilized non-invasive whole-body imaging and ex vivo organ analysis to evaluate the biodistribution of oral semaglutide [9][12] - A total of 25 male rats were used, with 22 allocated for dosing and 3 as untreated controls, examining both DehydraTECH and Rybelsus® equivalent compositions [12][13] Technology Overview - DehydraTECH is a patented drug delivery platform that enhances the absorption and effectiveness of various drugs, including those that cross the blood-brain barrier [14]
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Thenewswire· 2025-08-27 13:20
Core Viewpoint - Lexaria Bioscience Corp. will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8th to September 10th, 2025, highlighting its innovative drug delivery technology, DehydraTECH [1][3]. Company Overview - Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on improving the way drugs enter the bloodstream through oral delivery [1][3]. - The company operates a licensed in-house research laboratory and holds a strong intellectual property portfolio with 50 patents granted and additional patents pending worldwide [3]. Technology Highlights - DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform that enhances bio-absorption, reduces side effects, and improves drug delivery across the blood-brain barrier [3].
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
Thenewswire· 2025-08-14 13:20
Core Insights - Lexaria Bioscience Corp. has achieved a significant milestone in its Phase 1b GLP-1 study in Australia, completing the last patent last visit (LPLV) [1][2] - The study involved 126 participants and focused on evaluating various DehydraTECH formulations against a control arm using Rybelsus® [4][6] - Interim results have shown positive outcomes, particularly in safety and tolerability compared to the control arm, with a notable reduction in gastrointestinal adverse events [3] Study Details - The study included 24-25 overweight, obese, pre- or type 2 diabetic patients in each of the five study arms, with a total of 126 participants [4] - All doses were administered orally, with no injections involved, as Lexaria aims to shift the standard of care towards oral delivery [4] - The study arms included proprietary formulations of DehydraTECH-CBD and DehydraTECH-processed semaglutide, with the fifth arm evaluating DehydraTECH-tirzepatide [5][6][7] Future Objectives - Lexaria plans to release the final results of the study in the fourth quarter of 2025 [9] - The company is currently engaged in data analysis and sample processing, with a comprehensive database being developed [2] Technology Overview - DehydraTECH™ is Lexaria's patented drug delivery technology that enhances the bio-absorption of drugs through oral delivery, aiming to reduce side effects and improve efficacy [10] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [10]
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Thenewswire· 2025-07-23 13:25
Industry Overview - The GLP-1 weight loss and diabetes control sector is currently the fastest growing pharmaceutical sector globally, with revenue expectations exceeding $100 billion annually [2] - Updated projections indicate that the GLP-1 industry could generate over $156 billion in revenue by 2030, with a significant growth of 31% expected in 2025, reaching $70.1 billion [3] Challenges in the GLP-1 Sector - The GLP-1 industry faces significant challenges due to unwanted adverse effects, particularly gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation [4] - Discontinuation rates among GLP-1 users with type 2 diabetes are high, with studies showing that 47% to 64% of users stop their medication within 1 to 2 years, primarily due to gastrointestinal adverse effects [5][6] Company Innovations - Lexaria Bioscience Corp. has developed DehydraTECH technology, which aims to reduce side effects associated with GLP-1 drugs, potentially improving patient retention and industry growth [8][9] - DehydraTECH has shown promise in clinical testing for reducing gastrointestinal adverse effects in the top GLP-1 drugs, including semaglutide, tirzepatide, and liraglutide [10] Strategic Initiatives - Lexaria is pursuing a multi-faceted strategy to attract pharmaceutical companies to adopt its DehydraTECH technology, evidenced by a material transfer agreement with a pharmaceutical company announced in September 2024 [11]